ArticleInternational journal of clinical and experimental pathology2022
Using network pharmacology approaches to identify treatment mechanisms for codonopsis in esophageal cancer.
Article in International journal of clinical and experimental pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integrative Network Pharmacology and Molecular Docking Analysis Reveals the Multitarget Mechanisms of Pterostilbene in Neurodegenerative Diseases.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Facile synthesis of (4-phenylthiophen-2-yl)methyl 1-naphthoatesRSC advances · 2026Article
- The mechanistic study of codonopsis pilosula on laryngeal squamous cell carcinoma based on network pharmacology and experimental validation.Frontiers in pharmacology · 2025Article
- Strategies for the drug development of cancer therapeutics.Frontiers in pharmacology · 2025Review
- Comprehensive exploration of JQ1 and GSK2801 targets in breast cancer using network pharmacology and molecular modeling approaches.Computational and structural biotechnology journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe explored codonopsis mechanisms for the treatment of esophageal cancer using a network pharmacology approach. MATERIALS AND
methodsUsing the Laboratory of Systems Pharmacology website, codonopsis compounds and targets were gathered. After identifying esophageal cancer target intersections from the GeneCards website, possible codonopsis targets for esophageal cancer were screened. A protein-protein interaction (PPI) network diagram of protein targets was then constructed using the STRING database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genome (KEGG) pathway enrichment analyses were performed in R 3.6.0 software. A network diagram of "disease-drug-component-target-pathways" was also constructed using Cytoscape 3.7.1.
resultsWe screened 21 codonopsis compounds as possible esophageal cancer treatments and 31 drug-disease intersecting targets. GO enrichment analysis identified 778 biological process (BP) components, 15 cellular component (CC) components, and 50 molecular function (MF) components, and KEGG analyses identified 90 signaling pathways. Our analyses showed that p53 and PI3K-Akt signaling pathways (among others) were significant pathways in these processes.
conclusionsCodonopsis may be used to treat esophageal cancer by multiple components, targets, and pathways.
Indexed as
Identifiers
35265252PMC8902480What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.